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Fever in Sepsis: Still a Hot Topic
To the Editor:
With great interest, we read the paper by Bhavani and colleagues
(1), who report a novel method to distinguish between sepsis
phenotypes based on body temperature. Using trajectory
modeling, the authors identify four phenotypes, each displaying
distinct demographic characteristics, physiological parameters,
and prognosis. The data presented reveal that the so-called
hyperthermic, fast resolving patients, who presented with a
high temperature that decreased rapidly afterward, had the
lowest in-hospital mortality. In addition, a more swift
increase in temperature was also positively related to
survival. The authors plausibly argue that hyperthermic, fast
resolvers may be able to mount a strong, but nevertheless well-
balanced, inflammatory response, resulting in a better clinical
outcome.
What is currently missing is more solid evidence for whether or
not there is an immunological basis for the proposed temperature-
based phenotypes. Insight into the release of so-called endogenous
pyrogens (2), mainly represented by cytokines such as TNFa
(tumor necrosis factor a) and IL-6, could provide the missing link
between the underlying immune status and the body temperature
trajectories observed.
In the experimental human endotoxemia model, Escherichia
coli endotoxin is administrated intravenously to healthy
volunteers, inducing a standardized short-lasting systemic
inflammatory response, which captures relevant hallmarks of the
immune response observed in patients with sepsis (3). Serial
measurements of cytokines and body temperature during
endotoxemia allow for determination of their relationship.
Using data from 20 male subjects allocated to the control
group (no intervention other than bolus administration of
1 ng/kg endotoxin followed by continuous infusion of 1 ng/kg/h
endotoxin over the course of 3 h) of a recent interventional study
performed by our group (4), we analyzed the relationship between
peak plasma cytokine concentrations and body temperature
changes over time. We divided the subjects according to the
median cytokine levels, resulting in 10 low and 10 high cytokine
producers, and calculated the slope of the endotoxin-induced
temperature increase (Tempslope =D temperature increase/time to
peak temperature).
On average, plasma concentrations of TNFa, IL-6, and IL-10
reached their maximum at 2.5, 3, and 3.5 hours after endotoxin
administration, respectively, whereas peak temperatures were
observed 4 hours after endotoxin. Tempslope strongly correlated
with peak temperature (Spearman r = 0.92; P, 0.0001). In
subjects who produced high levels of the proinflammatory
cytokines IL-6 and TNFa, Tempslope was significantly higher
than in low proinflammatory cytokine producers, whereas
Tempslope did not differ between low and high producers of
antiinflammatory IL-10 (Figure 1). Spearman correlation
coefficients for the relationship between cytokines and
Tempslope were r = 0.75 for IL-6 (P, 0.0001) and r = 0.52
for TNFa (P = 0.02). Furthermore, peak temperatures were
reached earlier by high IL-6 and TNFa producers (high
responders: 3.66 0.1 vs. low responders: 4.56 0.2 h [P = 0.002]
and high responders: 3.76 0.2 vs. low responders: 4.46 0.2 h
[P = 0.02], respectively). After the peak, temperatures
gradually normalized, but the slope of the temperature
decrease did not correlate with levels of any of the measured
cytokines.
Taken together, these findings indicate that indeed higher levels
of proinflammatory, but not antiinflammatory, cytokines precede
a more potent and swift temperature increase. These data provide
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an immunological basis for the hypothesis of Bhavani and
colleagues, who state that hyperthermia may be the result of a more
proinflammatory phenotype, whereas a less pronounced immune
response might relate to a lower (or absent) temperature increase.
In view of the more favorable prognosis of hyperthermic patients
in whom temperature swiftly increases and quickly resolves,
a more pronounced but adequately balanced proinflammatory
response is of apparent benefit to the host. This further elucidates
why dozens of trials using immunosuppressive agents failed
to improve sepsis outcome and stresses the need for therapies
aimed at maintaining or restoring a well-functioning immune
system. n
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Reply to Leijte et al.
From the Authors:
We thank Dr. Leijte, Dr. Kox, and Dr. Pickkers for their
comments on our recent article on using temperature trajectories
to identify sepsis subphenotypes (1). Using group-based
trajectory modeling, we identified four subphenotypes with
different demographics, physiological characteristics, and
levels of inflammatory markers, and we hypothesized an
immunological basis for these subphenotypes. Supporting
our hypothesis of a connection between temperature and
immunological markers, Leijte and colleagues present a
human endotoxemia model revealing correlation between
temperature slopes and levels of endogenous pyrogens (IL-6
and TNFa [tumor necrosis factor a]) in healthy volunteers
after administration of Escherichia coli endotoxin (2). This
data provide evidence for the relationship between body
temperature and cytokine responses. In addition, the data
use dynamic temperature measurement (i.e., temperature
slopes) to study associations with cytokine levels. This
finding aligns with our work indicating that dynamic
measures of temperature (i.e., temperature trajectory,
variability, and slopes) may have more significance than
static measures.
Although the cytokine responses in this study provide
an immunological basis for our hypothesis, the systemic
inflammatory response is intentionally self-limited in these healthy
volunteers. We believe that measurement of cytokine levels in
naturally occurring sepsis would add further information to the
relationship between the thermoregulatory and immunological
systems. Sepsis is defined as a dysregulated immunological
response to infection. After the initial endotoxin-driven cytokine
storm in sepsis, there is a protracted dysregulated immunological
process that follows. We propose that temperature trajectories
may elucidate not only the initial cytokine response but also the
sustained immunological process in patients with sepsis. For
instance, hyperthermic, slow resolvers may have sustained high
levels of proinflammatory cytokines, whereas hyperthermic, fast
resolvers may have the same initial proinflammatory cytokine
storm followed by a defervescence process. We look forward to
studies such as those of Dr. Leijte, Dr. Kox, and Dr. Pickkers
to illuminate the relationship between temperature and the
immunological system. n
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Figure 1. Slope of the temperature increase (Tempslope) after endotoxin
administration for subjects with low and high peak levels of IL-6, TNFa
(tumor necrosis factor a), and IL-10. Data are presented as box-and-
whisker plots (Tukey).
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